AstraZeneca shares jump after J.P. Morgan reiterates Overweight
AZN rose about 2.16% intraday after J.P. Morgan reiterated an Overweight rating, citing six Phase III readouts due in 2027 with more than $10 billion in risk-adjusted peak sales.
P. Morgan reiterated an Overweight rating. The bank pointed to six Phase III readouts due in 2027 that together carry more than $10 billion in risk-adjusted peak sales, saying they should improve confidence in the company’s ability to keep growing.